Webcam Delivery of the Camperdown Program for Adolescents Who Stutter: A Phase II Trial

被引:38
|
作者
Carey, Brenda [1 ]
O'Brian, Sue [1 ]
Lowe, Robyn [1 ]
Onslow, Mark [1 ]
机构
[1] Univ Sydney, Australian Stuttering Res Ctr, Sydney, NSW 2006, Australia
关键词
stuttering; adolescents; Camperdown Program; telehealth; LONG-TERM; CLINICAL-TRIAL; SPEECH; ADULTS; SEVERITY; CHILDREN; RELIABILITY; STEREOTYPES; ATTITUDES; THERAPY;
D O I
10.1044/2014_LSHSS-13-0067
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
Purpose: This Phase II clinical trial examined stuttering adolescents' responsiveness to the Webcam-delivered Camperdown Program. Method: Sixteen adolescents were treated by Webcam with no clinic attendance. Primary outcome was percentage of syllables stuttered (%SS). Secondary outcomes were number of sessions, weeks and hours to maintenance, self-reported stuttering severity, speech satisfaction, speech naturalness, self-reported anxiety, self-reported situation avoidance, self-reported impact of stuttering, and satisfaction with Webcam treatment delivery. Data were collected before treatment and up to 12 months after entry into maintenance. Results: Fourteen participants completed the treatment. Group mean stuttering frequency was 6.1 %SS (range, 0.7-14.7) pretreatment and 2.8 %SS (range, 0-12.2) 12 months after entry into maintenance, with half the participants stuttering at 1.2 %SS or lower at this time. Treatment was completed in a mean of 25 sessions (15.5 hr). Self-reported stuttering severity ratings, self-reported stuttering impact, and speech satisfaction scores supported %SS outcomes. Minimal anxiety was evident either pre- or post-treatment. Individual responsiveness to the treatment varied, with half the participants showing little reduction in avoidance of speech situations. Conclusions: The Webcam service delivery model was appealing to participants, although it was efficacious and efficient for only half. Suggestions for future stuttering treatment development for adolescents are discussed.
引用
收藏
页码:314 / 324
页数:11
相关论文
共 50 条
  • [41] Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial
    Hovorka, Roman
    Allen, Janet M.
    Elleri, Daniela
    Chassin, Ludovic J.
    Harris, Julie
    Xing, Dongyuan
    Kollman, Craig
    Hovorka, Tomas
    Larsen, Anne Mette F.
    Nodale, Marianna
    De Palma, Alessandro
    Wilinska, Malgorzata E.
    Acerini, Carlo L.
    Dunger, David B.
    LANCET, 2010, 375 (9716): : 743 - 751
  • [42] Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    Bangert, Christine
    Irvine, Alan D.
    Weidinger, Stephan
    Johnson, Susan
    Lazariciu, Irina
    Koppensteiner, Herwig
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 77
  • [43] Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB72 - AB72
  • [44] Phase II trial of nimotuzumab in the treatment of refratory and relapsed high-grade gliomas in children and adolescents - Final report
    Bode, Udo
    Buchen, Steffanie
    Warmuth-Metz, Monika
    Pietsch, Torsten
    Bach, Ferdinand
    Whadelberg, Mareike
    Fleischhack, Gudrun
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 435 - 435
  • [45] Phase II trial of nimotuzumab in the treatment of refratory and relapsed high-grade gliomas in children and adolescents - final report
    Bode, U.
    Windelberg, M.
    Warmuth-Metz, M.
    Buchen, S.
    Pietsch, T.
    Bach, F.
    Fleischhack, G.
    ONKOLOGIE, 2008, 31 : 133 - 134
  • [46] Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents
    Bode, U.
    Buchen, S.
    Warmuth-Metz, M.
    Pietsch, T.
    Bach, F.
    Fleischhack, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine.
    Thomas, E.
    Perez, E. A.
    Mukhopadhyay, P.
    Lerzo, G.
    Pivot, X.
    Bosserman, L. D.
    Mullaney, B.
    Vahdat, L.
    Hortobagyi, G. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 42S - 42S
  • [48] A Phase II Trial of Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer Who Have Received Prior Taxane Therapy
    Pippen, John
    Elias, Anthony D.
    Neubauer, Marcus
    Stokoe, Christopher
    Vaughn, LaTrice G.
    Wang, Yanping
    Orlando, Mauro
    Shonukan, Oluwatoyin
    Muscato, Joseph
    O'Shaughnessy, Joyce A.
    Gralow, Julie
    CLINICAL BREAST CANCER, 2010, 10 (02) : 148 - 153
  • [49] Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy
    Denise A. Yardley
    Nancy Peacock
    Brooke Daniel
    Betrand Anz
    David C. Molthrop
    Sonalee K. Shroff
    Robyn Young
    Aleksander Jankov
    Amy Vander Woude
    Mythili Shastry
    Johanna Pasek
    Laura M. DeBusk
    John D. Hainsworth
    Breast Cancer Research and Treatment, 2020, 180 : 647 - 655
  • [50] Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy
    Yardley, Denise A.
    Peacock, Nancy
    Daniel, Brooke
    Anz, Betrand
    Molthrop, David C., Jr.
    Shroff, Sonalee K.
    Young, Robyn
    Jankov, Aleksander
    Vander Woude, Amy
    Shastry, Mythili
    Pasek, Johanna
    DeBusk, Laura M.
    Hainsworth, John D.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 647 - 655